Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Co-Pay Subsidies From Pharma At Odds With Goals Of Health Reform - Medco

This article was originally published in The Pink Sheet Daily

Executive Summary

From a health care reform perspective, the industry's increasing practice of providing subsidies that help keep patients on higher cost drugs "is a really bad thing to do" and "should not be allowed," Chairman Snow comments during PBM's earnings call.

You may also be interested in...



Can Pharma Industry Afford To Give Up More For Health Reform? PhRMA Calls President "Misinformed"

Pharmaceutical Research and Manufacturers trade group responds to President Obama's claim that the pharmaceutical industry can afford to give up more than the $80 billion previously agreed to.

PhRMA Health Reform Deal Is Not Binding On House, Rep. Waxman Declares

Waxman will keep pushing for Part D rebates to help fund closing the coverage gap, regardless of PhRMA's proposal for a different discount model. The good news for industry is that "dollars for donuts" remains the formula--and that even Waxman thinks industry will end up getting more than it gives.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel